@article{article40243773,
title   = {Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study},
author = {Robak, Tadeusz and Jin, Jie and Pylypenko, Halyna and Verhoef, Gregor and Siritanaratkul, Noppadol and Drach, Johannes and Raderer, Markus and Mayer, Jiri and Pereira, Juliana and Tumyan, Gayane},
year = {2018},
doi = {10.1016/S1470-2045(18)30685-5},
journal   = {Lancet oncology}
}